New hope for tough cancers: experimental drug ZG006 enters human trials
NCT ID NCT05978284
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or cannot tolerate them. The main goals are to find a safe dose and check for side effects. About 54 adults aged 18 to 75 will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?
- Can a black seed extract boost immunotherapy against a rare cancer?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a new drug tame advanced solid tumors?
- Can a remote approach bring clinical trials to lung cancer patients?